Navigation Links
Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Date:3/26/2008

QUEBEC CITY, March 26 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported dosing has commenced with its flagship product candidate, cetrorelix, the Company's lead luteinizing hormone-releasing hormone (LHRH) antagonist, in the second efficacy study of its Phase 3 program in benign prostatic hyperplasia (BPH), a non-cancerous enlargement of the prostate.

"We are very pleased to be on track with our Phase 3 clinical program for cetrorelix in BPH," said David J. Mazzo, Ph.D., President and CEO, Aeterna Zentaris. "Based on our new understanding of the multiple processes involved in the development of BPH and its symptoms, cetrorelix may offer a novel therapeutic approach to doctors and patients currently making trade-offs in care. We look forward to continuing our investigation of cetrorelix in this comprehensive clinical program."

The study, titled, "Cetrorelix pamoate in patients with symptomatic BPH: a double-blind, placebo-controlled efficacy study", will involve approximately 400 patients, and will assess an intermittent dosage regimen of cetrorelix as a potential safe and tolerable treatment providing prolonged improvement in BPH-related signs and symptoms. This Phase 3 trial, conducted in Europe under the supervision of lead investigator, Prof. Dr. Frans M.J. Debruyne, MD, of the Andros Mannenkliniek, Arnhem, The Netherlands, is part of the Company's Phase 3 program with cetrorelix being studied in approximately 1,500 patients in North America and Europe in men with symptomatic BPH.

About the Phase 3 Program with Cetrorelix in BPH

The first multi-center efficacy study for which first patient rand
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
2. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
3. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
4. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
5. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
6. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
7. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
8. AEterna Zentaris Announces Outcome of Managements Strategic Review
9. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
10. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
11. SPO Medical Begins Shipping PulseOx 6000(TM) and PulseOx 6100(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... (PRWEB) July 28, 2014 ... China Lubricant Industry” is a professional and ... Lubricant market. The report introduces Lubricant basic ... industry chain structure and industry overview. This ... China’s domestic market as well as global ...
(Date:7/28/2014)... July 28, 2014 Research and Markets ... Synthetic Biology Market 2014-2018" report to their offering. ... The term synthetic biology covers the designing and engineering ... well as the redesigning of natural biological systems that ... be a form of extreme genetic engineering because it ...
(Date:7/28/2014)... , July 28, 2014  David Hardison, Ph.D., ... by Deloitte , has been elected chairman of ... Consortium, a non-profit working to establish common protocols ... as it relates to electronic health records. ... mission of collaborating with organizations across the research ...
(Date:7/28/2014)... MO (PRWEB) July 28, 2014 ... and services that bring the power of genomics to ... inaugural Appistry Pipeline Challenge . , Two ... president of the National Center for Genome Resources, and ... Hospitals and Clinics of Kansas City. Rounding out the ...
Breaking Biology Technology:Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 2Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 3Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 4Global Synthetic Biology Market 2014-2018 2ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 2ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 3Appistry Names Industry Experts from the National Center for Genome Resources and Mercy Children's, Kansas City, to Judge Pipeline Challenge Competition 2
... Roche announced today the launch and immediate availability of the GS ... genetic variation detection in four key human genes using the company,s ... The sequence-based assays offer a new solution for cancer researchers investigating ... and RUNX1 genes, which are known to be associated ...
... Md., April 24, 2012 Northwest Biotherapeutics, Inc. (OTC Bulletin ... Institute in announcing that, working closely together over the course ... milestones in NW Bio,s DCVax®-L program for brain cancer in ... forward in the near term in Germany with both its ...
... DENVER, April 23, 2012  Today the Colorado legislature ... promotion of organ and tissue donation in Colorado. ... of Directors and community partners accepted the resolution, ... White (R-Hayden), Representative Dan Pabon (D-Denver) and Representative ...
Cached Biology Technology:Roche Launches 454 Sequencing Assays for High Sensitivity Genetic Variant Detection in Leukemia Samples to Drive Blood Cancer Research Worldwide 2Roche Launches 454 Sequencing Assays for High Sensitivity Genetic Variant Detection in Leukemia Samples to Drive Blood Cancer Research Worldwide 3Northwest Bio and Fraunhofer IZI Announce Milestones Reached 2Northwest Bio and Fraunhofer IZI Announce Milestones Reached 3Northwest Bio and Fraunhofer IZI Announce Milestones Reached 4Donor Alliance Honored By Colorado Legislature In Observation Of National Donate Life Month 2
(Date:7/28/2014)... for Alzheimer,s disease and other forms of dementia, but ... treatment. , University of Washington bioengineers have a designed ... of the body,s normal proteins into a state that,s ... disease, Type 2 diabetes and Lou Gehrig,s disease. The ... their normal state into an abnormally folded form by ...
(Date:7/28/2014)... the bug hunter, but the target of his work ... identified with special methods and instruments. Benjamin Hause, an ... Laboratory at Kansas State University, recently published an article ... is an important find in the United States. , ... know what it was," Hause said. "We used next-generation ...
(Date:7/28/2014)... (July 28, 2014)The Brain & Behavior Research Foundation ... and Freedman Prizes, recognizing exceptional clinical and basic ... by NARSAD Young Investigator Grants. The grants enable ... neurobiological and psychosocial research for the prevention, early ... affect one in four people. , Six young ...
Breaking Biology News(10 mins):New protein structure could help treat Alzheimer's, related diseases 2New protein structure could help treat Alzheimer's, related diseases 3Researcher using next-generation sequencing to rapidly identify pathogens 2Researcher using next-generation sequencing to rapidly identify pathogens 3The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 2The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 3The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 4
... Research Institute (LRI) today named 12 new grant recipients ... work across a broad spectrum of lupus research. All ... drive scientific discovery to ultimately prevent, treat, and cure ... grants go to both new and established lupus researchers ...
... may help gut bacteria bind to the gastrointestinal tract. The protein ... likely to be of real benefit to people. , "Probiotics need ... effect, and if they attach to surfaces in the gut they ... activity," says Dr Nathalie Juge from the Institute of Food Research. ...
... atomic-level action of a remarkable class of ring-shaped protein ... Berkeley National Laboratory (Berkeley Lab) using a state-of-the-art protein ... protein motors play pivotal roles in gene expression and ... biological cells, as well as infectious agents, such as ...
Cached Biology News:Lupus Research Institute announces 2009 novel research grants 2Lupus Research Institute announces 2009 novel research grants 3A sticky solution for identifying effective probiotics 2Atomic-level snapshot catches protein motor in action 2Atomic-level snapshot catches protein motor in action 3Atomic-level snapshot catches protein motor in action 4
... SizeSep 400 Spun Columns, 10. *SizeSep ... cDNAs > 400 base pairs in length. ... Sepharose CL-4B and pre-equilibrated in distilled water containing ... smaller than ~ 400 base pairs. ...
{3,8-diamino-5-[3-(diethylmethylammonio)propyl]-6-phenylphenanthridinium diiodide}. ,250 ug/ml Propidium Iodide (PI) in PBS....
Detects activated caspases in living cells. Simple/sensitive/straight-forward procedure takes only 30 minutes. Results can be analyzed by flow cytometry/fluorescence microscopy/fluorescence plate rea...
Anti-Mouse Qa.m7, Ascites (Clone 5035-50.1) (mouse IgM)...
Biology Products: